In a season when the weight-loss injections have become familiar to millions, a gathering of heart specialists in London has turned attention from the scale to the body's deeper clock. The studies presented at the European Society of Cardiology Congress describe concrete gains: fewer cases of heart failure, fewer deaths from Covid, and lower blood pressure once thought beyond treatment. From these, some physicians have begun to wonder whether such drugs might slow ageing itself, though that remains an inference rather than a finding. The question now rests with future trials, which must show w
Weight-loss jabs may slow ageing, but the evidence is still speculative, experts say
Slowed ageing is something experts expect, not something the studies measured
Mark
So what actually happened in London?
Mimi
Studies at the European Society of Cardiology Congress showed weekly doses of drugs like Ozempic and Wegovy can prevent heart failure, cut Covid deaths and reduce blood pressure once thought untreatable.
Mark
And that connects to ageing how?
Mimi
Dr. Harlan Krumholz of Yale argues that if you substantially improve cardiometabolic health, people are positioned to live longer and better. He said slowing ageing wouldn't surprise him.
Luke
Notice that's an opinion, not a result. Nobody here says a study measured biological ageing.
Mimi
Fair. The measured outcomes are the heart, Covid and blood pressure findings.
Mark
Why call them "health promoters"?
Mimi
Because the benefits look broader than weight loss, so some doctors want them seen as multi-purpose drugs.
Luke
Though we don't know the trial sizes, who was studied, or how big the effects were. The source doesn't say.
Mark
So is it a fountain of youth?
Mimi
Krumholz didn't claim that. He answered conditionally.
Luke
Right. What's missing is a controlled trial aimed at longevity. Until then, "slows ageing" is a hypothesis.
Der Puls
- A conference of cardiologists in London has stirred a bold question: can weekly weight-loss jabs slow the ageing of the body itself?
- Studies show Ozempic and Wegovy preventing heart failure, cutting Covid deaths, and bringing down blood pressure once thought untreatable.
- Doctors are pushing to recast these injections as broad 'health promoters' rather than mere aids for losing weight.
- Yet the ageing claim rests on expert opinion, not measured results, and the scale of the benefits remains unclear from the reporting.
- The drugs' reach is widening, but the verdict on longevity waits on controlled trials designed to test lifespan directly.
In a season when the weight-loss injections have become familiar to millions, a gathering of heart specialists in London has turned attention from the scale to the body's deeper clock. The studies presented at the European Society of Cardiology Congress describe concrete gains: fewer cases of heart failure, fewer deaths from Covid, and lower blood pressure once thought beyond treatment. From these, some physicians have begun to wonder whether such drugs might slow ageing itself, though that remains an inference rather than a finding. The question now rests with future trials, which must show whether a longer and better life can truly be measured.
At the European Society of Cardiology Congress in London, the largest gathering of its kind, a series of studies on weekly weight-loss injections has prompted some doctors to ask a bigger question: could Ozempic and Wegovy slow the body's biological ageing?
The findings presented there point to benefits beyond what researchers first expected. Weekly doses were shown to prevent heart failure and reduce deaths from Covid, and to lower high blood pressure that had previously seemed untreatable. These results have led some doctors to argue the injections are better understood as multi-purpose 'health promoters' than as simple aids for weight loss.
The most direct comment came from Dr. Harlan Krumholz of Yale. Asked whether the drugs were a fountain of youth, he declined to say yes. Improving someone's cardiometabolic health, he reasoned, places them in a position to live longer and better, and he would not be surprised if this slowed ageing. His framing was conditional, not a reported result.
That distinction matters. The studies measured heart failure, Covid deaths, and blood pressure, while the leap to biological ageing is an expert inference. The account does not describe trial sizes, participants, or how ageing was assessed. What it does show is a shift in how cardiologists view these drugs, from weight-loss tools to protectors of heart and metabolic health. Whether that reaches longevity remains open, and only controlled trials testing lifespan or ageing directly can move the idea from plausible to proven.
At the European Society of Cardiology Congress in London, the world's largest cardiology conference, a run of studies on weekly weight-loss injections has led some doctors to ask a question that goes well past the bathroom scale: could drugs like Ozempic and Wegovy slow the body's biological ageing?
The evidence presented there, according to the reporting, points to what one account describes as far-reaching benefits beyond what researchers first imagined. Studies at the congress found that weekly doses of the jabs can prevent heart failure and cut deaths from Covid. They also found the drugs can reduce high blood pressure that had previously been considered untreatable.
That breadth is behind an argument now being made by some doctors: the injections should be thought of as multi-purpose drugs, even "health promoters", rather than simply an aid for people trying to lose weight. Doctors cited in the coverage say there is increasing evidence the drugs may help people live "longer and better".
The most direct statement on ageing came from Dr. Harlan Krumholz, Professor of Medicine at Yale University School of Medicine. Asked whether this amounts to a fountain of youth, he did not say yes. His reasoning was conditional: if you substantially improve someone's cardiometabolic health, he said, you put them in a position to live longer and better. He added that it would not surprise him if improving people's health this way actually slows down the ageing process.
The wording matters. Krumholz framed slowed ageing as something that would not surprise him, not as a result demonstrated at the congress. What the studies reported are specific clinical outcomes: heart failure prevention, fewer Covid deaths, and blood pressure reductions. The step from those outcomes to a claim about biological ageing is an inference by experts, not a measured finding described in the source.
The source does not give trial sizes, participant groups, or the magnitude of the effects, so the scale of the benefits cannot be judged from this account. It also does not say how biological ageing was assessed, or whether any study measured it directly.
What the coverage does establish is a shift in how some cardiologists are talking about these drugs, from weight-loss tools to broader protectors of heart and metabolic health. Whether that extends to longevity is the open question. Watch for controlled trials designed to test lifespan or ageing effects directly, which would be needed to move the claim from plausible to proven.
Bemerkenswerte Zitate
It wouldn't surprise me that improving people's health this way actually slows down the ageing process.— Dr. Harlan Krumholz, Professor of Medicine, Yale University School of Medicine
Möchten Sie die ganze Geschichte?
Das Original lesen bei PerthNow ↗
Health & Medicine